CDNA Quote, Financials, Valuation and Earnings

Electromed has a net margin of -12.23% compared to CareDx's net margin of 12.06%. CareDx's return on equity of 18.96% beat Electromed's return on equity of 16.57%.

CareDx has a consensus price target of $29.29, signalling upside risk potential of 55.36%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 74.31%. Given that Electromed has higher upside potential than CareDx, analysts believe Electromed is more attractive than CareDx.

CareDx has a beta of 2.192, which suggesting that the stock is 119.241% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $84.7M, which are larger than Electromed quarterly revenues of $15.7M. CareDx's net income of -$10.4M is lower than Electromed's net income of $1.9M. Notably, CareDx's price-to-earnings ratio is 16.39x while Electromed's PE ratio is 27.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.13x versus 3.18x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Senseonics Holdings has a net margin of -12.23% compared to CareDx's net margin of -227.89%. CareDx's return on equity of 18.96% beat Senseonics Holdings's return on equity of -1761.77%.

CareDx has a consensus price target of $29.29, signalling upside risk potential of 55.36%. On the other hand Senseonics Holdings has an analysts' consensus of $1.55 which suggests that it could grow by 225.9%. Given that Senseonics Holdings has higher upside potential than CareDx, analysts believe Senseonics Holdings is more attractive than CareDx.

CareDx has a beta of 2.192, which suggesting that the stock is 119.241% more volatile than S&P 500. In comparison Senseonics Holdings has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.434%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senseonics Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. Senseonics Holdings pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $84.7M, which are larger than Senseonics Holdings quarterly revenues of $6.3M. CareDx's net income of -$10.4M is higher than Senseonics Holdings's net income of -$14.3M. Notably, CareDx's price-to-earnings ratio is 16.39x while Senseonics Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.13x versus 13.17x for Senseonics Holdings. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -12.23% compared to CareDx's net margin of -2201.34%. CareDx's return on equity of 18.96% beat VolitionRX's return on equity of --.

CareDx has a consensus price target of $29.29, signalling upside risk potential of 55.36%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 282.86%. Given that VolitionRX has higher upside potential than CareDx, analysts believe VolitionRX is more attractive than CareDx.

CareDx has a beta of 2.192, which suggesting that the stock is 119.241% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $84.7M, which are larger than VolitionRX quarterly revenues of $246.4K. CareDx's net income of -$10.4M is lower than VolitionRX's net income of -$5.4M. Notably, CareDx's price-to-earnings ratio is 16.39x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.13x versus 52.93x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -12.23% compared to CareDx's net margin of 0.18%. CareDx's return on equity of 18.96% beat Xtant Medical Holdings's return on equity of -26.62%.

CareDx has a consensus price target of $29.29, signalling upside risk potential of 55.36%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 144.76%. Given that Xtant Medical Holdings has higher upside potential than CareDx, analysts believe Xtant Medical Holdings is more attractive than CareDx.

CareDx has a beta of 2.192, which suggesting that the stock is 119.241% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $84.7M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. CareDx's net income of -$10.4M is lower than Xtant Medical Holdings's net income of $58K. Notably, CareDx's price-to-earnings ratio is 16.39x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.13x versus 0.80x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.